Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Chao Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8203-1457; OpenAlex author ID A5020844882. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4. Last author DOI 10.1016/j.drup.2024.101171↗
  2. Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis. Co-author DOI 10.1038/s41419-022-04669-0↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dijie Zheng · 2 shared papers, 2022–2025 · strength 0.43
  2. Zhiwei He · 2 shared papers, 2022–2025 · strength 0.43
  3. Futang Li · 1 shared paper, 2025 · strength 0.28
  4. Zhirui Zeng · 1 shared paper, 2025 · strength 0.28
  5. Changhao Wu · 1 shared paper, 2025 · strength 0.28
  6. Shiyu Chen · 1 shared paper, 2022 · strength 0.15
  7. Kun Cai · 1 shared paper, 2022 · strength 0.15
  8. Lin Li · 1 shared paper, 2022 · strength 0.15
  9. Yanqing Liu · 1 shared paper, 2022 · strength 0.15
  10. Cheng-Yi Sun · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.